https://www.yiliao.com/index.php?action=history&feed=atom&title=%E7%99%BE%E5%88%A9%E5%A4%A9%E6%81%92
百利天恒 - 版本历史
2026-04-18T18:29:20Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E7%99%BE%E5%88%A9%E5%A4%A9%E6%81%92&diff=314529&oldid=prev
223.160.136.36：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-15T07:21:36Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[百利天恒]]</strong>（<strong>[[Biokin Pharmaceutical]]</strong>）是一家总部位于[[中国]][[成都]]，并在[[美国]][[西雅图]]设有研发中心（<strong>[[SystImmune]]</strong>）的全球化[[创新药]]领军企业。公司专注于<strong>[[抗体偶联药物]]</strong>（<strong>[[ADC]]</strong>）、<strong>[[双特异性抗体]]</strong>及<strong>[[四特异性抗体]]</strong>（[[GNC]]平台）的开发。[[百利天恒]]凭借其旗舰产品<strong>[[BL-B01D1]]</strong>（全球首款进入临床的[[EGFR]]×[[HER3]]双靶点ADC）与全球制药巨头<strong>[[百时美施贵宝]]</strong>（<strong>[[BMS]]</strong>）达成了涉及[[84亿美元]]的战略授权合作，刷新了国产[[创新药]]出海的历史纪录。当前，公司已构建起涵盖[[非小细胞肺癌]]、[[乳腺癌]]及[[消化道肿瘤]]的深厚[[精准医疗]]管线。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #ffffff 0%, #e0f2fe 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[百利天恒]] (Biokin)</div><br />
<div style="font-size: 0.75em; opacity: 0.85; margin-top: 4px;">ADC与多抗领域全球领军者 · 点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<div style="padding: 12px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">[[ADC]]与[[GNC]]研发技术矩阵</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心资产：[[BL-B01D1]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">股票代码</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">688506.SH</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">首席执行官</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[朱义]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">关键技术</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[ADC]]•[[GNC]]•[[BsAb]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">核心靶点</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[EGFR]] / [[HER3]] / [[PD-L1]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[Entrez]]ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">1956([[EGFR]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">研发中心</th><br />
<td style="padding: 12px; color: #0f172a;">[[成都]] / [[西雅图]]</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">技术核心：从双抗ADC到四特异性抗体</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[百利天恒]]的核心竞争力在于其对复杂[[生物大分子]]结构的工程化能力，主要体现在以下三大平台：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>[[双特异性ADC]]平台：</strong>代表作<strong>[[BL-B01D1]]</strong>通过同时靶向[[EGFR]]和[[HER3]]，不仅增强了对肿瘤细胞的识别特异性，还能通过阻断[[旁路信号]]协同克服[[耐药性]]，这种“双靶点+强效载药”的设计显著拓宽了[[治疗窗口]]。</li><br />
<li style="margin-bottom: 12px;"><strong>[[GNC]]四抗平台：</strong>作为全球首创的[[四特异性抗体]]平台，该技术能同时结合肿瘤抗原、[[CD3]]、[[CD28]]及[[4-1BB]]。通过激活自身[[T细胞]]并引导其精准杀伤肿瘤，旨在解决[[实体瘤]]免疫治疗浸润不足的瓶颈。</li><br />
<li style="margin-bottom: 12px;"><strong>[[全产业链整合]]：</strong>公司实现了从[[抗体发现]]、[[抗原]]制备到[[化学合成]]、[[偶联工艺]]的完全自主研发，确保了如<strong>[[SI-B001]]</strong>（[[EGFR]]×[[HER3]]双抗）等管线的高效推进。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">核心创新管线与临床矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 25px auto; width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">产品代码</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">靶点/类别</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">当前临床/商业地位</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[BL-B01D1]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[EGFR]]×[[HER3]] [[ADC]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">核心大单品，[[III期]]研究推进中；获[[BMS]]全球合作，针对[[肺癌]]展现突破性疗效。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[SI-B001]] ([[EMB01]])</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[EGFR]]×[[HER3]] [[双抗]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">处于[[III期]]临床阶段，旨在解决[[EGFR-TKI]]耐药后的续贯治疗。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[GNC-038]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[四特异性抗体]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">针对[[非霍奇金淋巴瘤]]，作为全球首款进入临床的四抗备受期待。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[BL-M07D1]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[HER2]] [[ADC]]</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">针对[[乳腺癌]]及[[胃癌]]，采用新型[[Topoisomerase I]]抑制剂载荷。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">发展战略：立足中国，驱动全球合作</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[百利天恒]]在当前的发展路径中体现了从“[[精细化仿制]]”向“[[源头创新]]”的彻底转型：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>[[全球同步研发]]：</strong>通过位于西雅图的[[SystImmune]]平台，第一时间对接全球前沿[[免疫学]]理论，实现产品管线的[[First-in-class]]定位。</li><br />
<li style="margin-bottom: 12px;"><strong>[[License-out]]策略：</strong>通过与[[百时美施贵宝]]等[[大药企]]（[[MNC]]）合作，利用其全球商业化网络加速创新药在[[欧美]]市场的落地。</li><br />
<li style="margin-bottom: 12px;"><strong>[[多适应症]]突围：</strong>针对[[非小细胞肺癌]]这一大病种，通过[[ADC]]、[[双抗]]、[[化疗]]等多维度联用，构建竞争壁垒。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[BL-B01D1]]：</strong>目前国产出海交易额最高的[[ADC]]药物。</li><br />
<li style="margin-bottom: 8px;"><strong>[[HER3]]：</strong>肿瘤旁路激活的关键受体，是[[百利天恒]]差异化布局的重中之重。</li><br />
<li style="margin-bottom: 8px;"><strong>[[GNC平台]]：</strong>代表了当前[[多抗]]技术的最高复杂度与创新深度。</li><br />
<li style="margin-bottom: 8px;"><strong>[[百时美施贵宝]] (BMS)：</strong>[[百利天恒]]最重要的全球战略合作伙伴。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Zhang L, et al. (2024).</strong> <em>BL-B01D1, a first-in-class EGFRxHER3 bispecific ADC, in patients with locally advanced or metastatic solid tumors.</em> <strong>[[The Lancet Oncology]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[权威点评]：该研究证实了双靶点ADC在克服EGFR单靶点治疗耐药方面的巨大潜力。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Biokin Pharmaceutical. (2025).</strong> <em>Strategic Partnership Update with Bristol Myers Squibb on BL-B01D1 Global Development.</em> <strong>[[SSE Disclosures]]</strong>.<br><br />
<span style="color: #475569;">[核心价值]：记录了百利天恒创新管线走向国际舞台的商业里程碑。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
[[百利天恒]] ([[Biokin]]) 企业诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[EGFR]]•[[HER3]]•[[HER2]]•[[PD-1]]•[[CD3]]•[[4-1BB]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研发实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[百利药业]]•[[SystImmune]]•[[百利天恒研发中心]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略合作伙伴</td><br />
<td style="padding: 10px 15px; color: #334155;">[[百时美施贵宝]](BMS)•[[NMPA]]•[[FDA]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研究前沿</td><br />
<td style="padding: 10px 15px; color: #334155;">[[多靶点ADC的抗耐药机制]]•[[四特异性抗体激活T细胞疗法]]•[[ADC联合PD-1一线肺癌探索]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.136.36